PT - JOURNAL ARTICLE AU - Daniels, Nicky AU - Moerkerke, Matthijs AU - Steyaert, Jean AU - Bamps, Annelies AU - Debbaut, Edward AU - Prinsen, Jellina AU - Tang, Tiffany AU - Van der Donck, Stephanie AU - Boets, Bart AU - Alaerts, Kaat TI - Effects of multiple-dose intranasal oxytocin treatment on social responsiveness in children with autism: A randomized, placebo-controlled trial AID - 10.1101/2022.04.20.22274106 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.20.22274106 4099 - http://medrxiv.org/content/early/2022/04/21/2022.04.20.22274106.short 4100 - http://medrxiv.org/content/early/2022/04/21/2022.04.20.22274106.full AB - In the past decade, intranasal administration of the neuropeptide oxytocin is increasingly explored as a new treatment for reducing the core symptoms of autism spectrum disorder (ASD). The efficacy of continual oxytocin treatment in school-aged children with ASD is, however, not well established. Using a double-blind, randomized, placebo-controlled, parallel design, the current trial explored the effects of four weeks of intranasal oxytocin treatment (12 IU, twice daily) on social functioning in pre-pubertal school-aged children (aged 8-12 years, 61 boys, 16 girls). The double-blind phase was followed by a four-week single-blind extension phase during which all participants received intranasal oxytocin. In the double-blind phase, no treatment-specific effects were identified in the primary outcome assessing social functioning (parent-rated Social Responsiveness Scale), as well as on secondary outcomes assessing repetitive behaviors, anxiety, and attachment. Exploratory moderator analyses revealed that children who received the oxytocin treatment in combination with concomitant psychosocial treatment displayed a greater benefit than those who received psychosocial treatment or oxytocin alone. A modulating effect of parents’ beliefs about allocated treatment was also identified, indicating that parents who believed their child assigned to the active treatment reported greater benefit than those who believed their child received placebo, particularly in the actual oxytocin group. Finally, participants who were allocated to receive the placebo treatment during the double-blind phase of the trial and later crossed-over to receive the active treatment during the single-blind extension phase, displayed a significant within-group improvement in social responsiveness, over and above the placebo-induced improvements noted in the first phase. While no overall treatment-specific improvements were identified, our results provide important indications that clinical efficacy can be augmented when oxytocin administration is paired with targeted psychosocial interventions that similarly stimulate socio-communicative behaviors. Future trials are urged to further elucidate the potential of embedding oxytocin treatment within a socially stimulating context.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudract 2018-000769-35Funding StatementThis study was funded by an internal C1 fund of the KU Leuven [ELG-D2857-C14/17/102], a Doctor Gustave Delport fund of the King Baudouin Foundation and the Branco Weiss fellowship of the Society in Science - ETH Zurich granted to KA. JP is supported by the Marguerite-Marie Delacroix foundation and a postdoctoral fellowship of the Flanders Fund for Scientific Research (FWO; 1257621N).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee Research UZ / KU Leuven at KU Leuven gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on reasonable request from the corresponding author, KA. The data are not publicly available due to privacy restrictions.